Protagenic Therapeutics (PTIX) Competitors $0.25 -0.01 (-3.77%) Closing price 03:53 PM EasternExtended Trading$0.25 +0.00 (+0.80%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends PTIX vs. ADXN, OBSV, AYTU, HOTH, KLTO, CYCN, ONVO, OMGA, BFRI, and PWUPShould you be buying Protagenic Therapeutics stock or one of its competitors? The main competitors of Protagenic Therapeutics include Addex Therapeutics (ADXN), ObsEva (OBSV), Aytu BioPharma (AYTU), Hoth Therapeutics (HOTH), Klotho Neurosciences (KLTO), Cyclerion Therapeutics (CYCN), Organovo (ONVO), Omega Therapeutics (OMGA), Biofrontera (BFRI), and PowerUp Acquisition (PWUP). These companies are all part of the "pharmaceutical products" industry. Protagenic Therapeutics vs. Addex Therapeutics ObsEva Aytu BioPharma Hoth Therapeutics Klotho Neurosciences Cyclerion Therapeutics Organovo Omega Therapeutics Biofrontera PowerUp Acquisition Addex Therapeutics (NASDAQ:ADXN) and Protagenic Therapeutics (NASDAQ:PTIX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation, dividends and community ranking. Which has more volatility & risk, ADXN or PTIX? Addex Therapeutics has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Protagenic Therapeutics has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Which has better earnings and valuation, ADXN or PTIX? Protagenic Therapeutics has lower revenue, but higher earnings than Addex Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Protagenic Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAddex Therapeutics$556.05K14.58-$11.76M-$0.34-22.50Protagenic TherapeuticsN/AN/A-$5M-$1.27-0.20 Is ADXN or PTIX more profitable? Addex Therapeutics has a net margin of 850.30% compared to Protagenic Therapeutics' net margin of 0.00%. Addex Therapeutics' return on equity of -112.43% beat Protagenic Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Addex Therapeutics850.30% -112.43% -77.95% Protagenic Therapeutics N/A -308.97%-228.73% Do insiders & institutionals believe in ADXN or PTIX? 16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 8.0% of Protagenic Therapeutics shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by insiders. Comparatively, 35.0% of Protagenic Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in ADXN or PTIX? Addex Therapeutics received 15 more outperform votes than Protagenic Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformAddex TherapeuticsOutperform Votes1551.72% Underperform Votes1448.28% Protagenic TherapeuticsN/AN/A Do analysts recommend ADXN or PTIX? Addex Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 292.16%. Given Addex Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Addex Therapeutics is more favorable than Protagenic Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Protagenic Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to ADXN or PTIX? In the previous week, Addex Therapeutics had 1 more articles in the media than Protagenic Therapeutics. MarketBeat recorded 1 mentions for Addex Therapeutics and 0 mentions for Protagenic Therapeutics. Addex Therapeutics' average media sentiment score of 0.99 beat Protagenic Therapeutics' score of 0.00 indicating that Addex Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Addex Therapeutics Positive Protagenic Therapeutics Neutral SummaryAddex Therapeutics beats Protagenic Therapeutics on 13 of the 16 factors compared between the two stocks. Remove Ads Get Protagenic Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTIX vs. The Competition Export to ExcelMetricProtagenic TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.81M$7.11B$5.73B$8.12BDividend YieldN/A2.77%4.41%4.09%P/E Ratio-0.206.3224.4819.28Price / SalesN/A237.41402.1289.09Price / CashN/A65.6738.1134.64Price / Book0.306.626.904.38Net Income-$5M$141.83M$3.18B$247.04M7 Day Performance-8.79%0.44%0.81%2.01%1 Month Performance-1.19%-7.39%0.40%-8.31%1 Year Performance-80.69%-4.69%13.84%5.72% Protagenic Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTIXProtagenic Therapeutics0.4911 of 5 stars$0.25-3.8%N/A-78.4%$1.81MN/A-0.202ADXNAddex Therapeutics2.5542 of 5 stars$7.50-2.7%$30.00+300.3%-38.1%$7.95M$556,045.00-22.0430Upcoming EarningsShort Interest ↓Gap DownOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150AYTUAytu BioPharma1.5132 of 5 stars$1.26+0.8%N/A-59.2%$7.77M$77.23M-0.87160Positive NewsHOTHHoth Therapeutics3.4409 of 5 stars$1.10+0.9%$4.00+263.6%-7.8%$7.59MN/A-0.834Short Interest ↓News CoverageKLTOKlotho NeurosciencesN/A$0.28-3.7%N/AN/A$7.55MN/A0.00N/AGap DownCYCNCyclerion Therapeutics0.7947 of 5 stars$2.63-6.1%N/A-19.4%$7.13M$2M-2.1630Positive NewsONVOOrganovo0.4115 of 5 stars$0.41-9.0%N/A-63.6%$7.04M$122,000.00-0.4820Analyst ForecastStock SplitOMGAOmega Therapeutics2.0044 of 5 stars$0.13-21.8%$9.20+7,260.0%-96.4%$6.92M$8.10M-0.09120Gap UpBFRIBiofrontera3.1546 of 5 stars$0.88-4.3%$7.00+695.5%-21.7%$6.82M$35.36M-0.3970Upcoming EarningsNews CoverageGap DownPWUPPowerUp AcquisitionN/A$0.86flatN/A-94.2%$6.68MN/A0.00N/AHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Addex Therapeutics Alternatives ObsEva Alternatives Aytu BioPharma Alternatives Hoth Therapeutics Alternatives Klotho Neurosciences Alternatives Cyclerion Therapeutics Alternatives Organovo Alternatives Omega Therapeutics Alternatives Biofrontera Alternatives PowerUp Acquisition Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTIX) was last updated on 3/19/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagenic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagenic Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
